Enthera’s ‘Regenerative Immunology’ Approach Breaks New Ground In Diabetes And IBD
Exclusive Interview With CEO Giovanni Amabile
Italy’s Enthera Pharmaceuticals is targeting a novel stem cell apoptosis pathway involved in several autoimmune diseases, with the aim of restoring cell and organ functions to their original state. The biotech recently closed a €35m series A financing round, the largest the country has seen to date.
You may also be interested in...
Advisory committee members say Provention Bio’s meta-analysis of biomarker data from other type 1 diabetes trials cannot serve as confirmatory evidence to satisfy the ‘substantial evidence’ standard, creating a potentially awkward situation for the agency when it comes to making an approval decision.
Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.
UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.